検索結果

: Mr. Naoyuki Mochida; hereinafter: Mochida) as an eye drop treatment for Dry Eye Disease (DED). We are pleased to announce successful completion of Phase III clinical trials in Japan, which consisted...

: Mr. Naoyuki Mochida; hereinafter: Mochida) as an eye drop treatment for Dry Eye Disease (DED). We are pleased to announce successful completion of Phase III clinical trials in Japan, which consisted...

hereinafter: Mochida) and licensed to Senju as an eye drop treatment for Dry Eye Disease (DED). We are pleased to announce today that it has been applied for manufacturing and marketing approval in J...

compound having the development code SJP-0008 was granted by the Ministry of Health, Labor and Welfare (HMLW) on June 19, 2024, as an orphan drug of the Central Retinal Artery Occlusion (CRAO). Orpha...

hereinafter: Mochida) and licensed to Senju as an eye drop treatment for Dry Eye Disease (DED). We are pleased to announce today that it has been applied for manufacturing and marketing approval in J...